Abstract: The invention provides a power distribution and drive system for a remotely underwater operated vehicle ROV, comprises: a high-voltage DC power supply device, located above the water surface to provide high-voltage DC voltage to the ROV; a DC buck conversion device, connected to the high-voltage DC power supply device through a cable for converting the high-voltage DC voltage to a low-voltage DC voltage to supply power to the ROV, wherein the DC buck conversion device comprises multiple parallel DC conversion modules, each DC conversion module bearing an average load current to supply power to the ROV; and at least one thruster, which comprises a propeller, a synchronous motor, and a driver.

Abstract: The invention relates to an information security protection method and apparatus, and a computer-readable storage medium. The information security protection method comprises the steps of: allocating a train control and monitoring system to an intranet region, and performing region boundary security protection on the train control and monitoring system; performing communication network security protection on the train control and monitoring system; and performing terminal device security protection on the train control and monitoring system.

Abstract: Provided are a method and system for controlling a voltage. The method includes: acquiring a current output voltage of an inverter; calculating a current voltage error of the current output voltage relative to a given output voltage; inputting the current voltage error into a fuzzy controller to determine a target output voltage of the inverter; determining an amplitude adjustment command based on a difference between an amplitude of the target output voltage and an amplitude of the current output voltage; determining a phase adjustment command based on a difference between a phase of the target output voltage and a phase of the current output voltage; and adjusting an amplitude and a phase of an output voltage of the inverter according to the amplitude adjustment command and the phase adjustment command respectively, to maintain the output voltage of the inverter within a preset range.

Abstract: Provided are a method and system for controlling a voltage. The method includes: acquiring a current output voltage of an inverter; calculating a current voltage error of the current output voltage relative to a given output voltage; inputting the current voltage error into a fuzzy controller to determine a target output voltage of the inverter; determining an amplitude adjustment command based on a difference between an amplitude of the target output voltage and an amplitude of the current output voltage; determining a phase adjustment command based on a difference between a phase of the target output voltage and a phase of the current output voltage; and adjusting an amplitude and a phase of an output voltage of the inverter according to the amplitude adjustment command and the phase adjustment command respectively, to maintain the output voltage of the inverter within a preset range.

Abstract: The present invention provides a composition, use of the composition in preparing drugs for treating and/or relieving depigmentation disorders, and a preparation comprising the composition. The composition comprises fluoxetine and vitamin D3 or derivatives of vitamin D3. In the composition, fluoxetine in combination with VD3 derivatives can improve melanogenesis. Compared with VD3 derivatives or fluoxetine when used alone, fluoxetine in combination with VD3 derivatives can not only improve the curative effect, but also reduce the dosage of VD3 derivatives or fluoxetine and the occurrence of toxic and side effects.

Abstract: A braking force distribution method and system for multiple marshalling train compartments are provided. The method includes: determining a current train compartment of multiple target marshalling train compartments, calculating current axel loads of axels of the current train compartment, and distributing braking forces for the axels of the current train compartment in a positive correlation manner based on the current axel loads of the axels. The braking forces of the axels are distributed by using an axel load compensation technology. A braking force generated by an axle with a small axle load is reduced according to a load-decreasing amount of the axle load, while a braking force generated by an axle with a great axle load is increased according to a load-increasing amount of the axle load, so that the braking forces generated by the axles match the axle loads.

Abstract: Disclosed are a compound pharmaceutical composition containing Cichorium glandulosum Boiss et Hout as a lipid-lowering active ingredient and the use of the composition for preparing a drug for treating or preventing lipid metabolism disorders, wherein the composition comprises a pharmaceutically active ingredient and a pharmaceutically acceptable carrier, wherein the pharmaceutically active ingredient consists of quercetin-3-O-?-D-glucuronoside, isoquercitrin and quercetin at a molar ratio of 1.1-2.4:1.3-3.3:1.2-3.1.

Abstract: A rotor temperature monitoring method and system for a permanent magnet synchronous motor are provided. According to the method and system, an a-phase line current and a b-phase line current of a stator of a permanent magnet synchronous motor are obtained as a first line current and a second line current; further, a line voltage between the a-phase and the b-phase of the stator is obtained and a rotating speed of the rotor of the permanent magnet synchronous motor is obtained; and then, the first line current, the second line current, the line voltage, the rotating speed of the rotor, an inductance parameter of the permanent magnet synchronous motor and a temperature characteristic equation of a permanent magnet of the rotor are substituted into a preset rotor permanent magnet temperature expression to calculate and obtain the temperature of the rotor.

Abstract: Disclosed is a composition containing active components of Dracocephalum moldavica L. against myocardial ischemia-reperfusion injury (MIRI). The composition consists of active components and a pharmaceutically acceptable carrier, wherein the active components comprise luteolin, kaempferol and luteolin-7-O-glucoside. Pharmacodynamic experiments show that these three components can be combined together to synergistically treat myocardial ischemia-reperfusion injury.

Abstract: A method and a system for correcting an initial zero position deviation are provided, which is applied to a permanent magnet synchronous motor and a resolver. The method includes: driving a rotor of the permanent magnet synchronous motor to rotate at a constant speed; acquiring counter electromotive forces of a stator of the permanent magnet synchronous motor and a position of a rotor of the resolver; calculating a space vector phase angle ?1 based on the counter electromotive forces; acquiring a rotation angle ?2 measured by the resolver; calculating an installation deviation ?? corresponding to the space vector phase angle ?1 and the rotation angle ?2; and adjusting a position of the resolver until the installation deviation ?? meets a precision requirement.

Abstract: A method and a system for correcting an initial zero position deviation are provided, which is applied to a permanent magnet synchronous motor and a resolver. The method includes: driving a rotor of the permanent magnet synchronous motor to rotate at a constant speed; acquiring counter electromotive forces of a stator of the permanent magnet synchronous motor and a position of a rotor of the resolver; calculating a space vector phase angle ?1 based on the counter electromotive forces; acquiring a rotation angle ?2 measured by the resolver; calculating an installation deviation ?? corresponding to the space vector phase angle ?1 and the rotation angle ?2; and adjusting a position of the resolver until the installation deviation ?? meets a precision requirement.

Abstract: A control method for restarting a permanent magnet synchronous motor (PMSM) in a rotating condition, and a device and a system thereof are provided. In the method, an electrical angular speed ?e of the PMSM is obtained based on a speed of a trailer to obtain a back electromotive force of the PMSM. The back electromotive force is compared with a voltage at a side of an inverter, and if the electromotive force of the permanent magnet synchronous motor is higher than the voltage at the side of the inverter, the restarting of the PMSM is forbidden, otherwise, the restarting of the PMSM is allowed. Therefore, in the present disclosure, the low-speed operating condition and the high-speed operating condition correspond to different position angles of the rotor, and the PMSM is started based on the position angle of the rotor.

Abstract: A braking force distribution method and system for multiple marshalling train compartments are provided. The method includes: determining a current train compartment of multiple target marshalling train compartments, calculating current axel loads of axels of the current train compartment, and distributing braking forces for the axels of the current train compartment in a positive correlation manner based on the current axel loads of the axels. The braking forces of the axels are distributed by using an axel load compensation technology. A braking force generated by an axle with a small axle load is reduced according to a load-decreasing amount of the axle load, while a braking force generated by an axle with a great axle load is increased according to a load-increasing amount of the axle load, so that the braking forces generated by the axles match the axle loads.

Abstract: Disclosed in the present invention are a bis-?-carboline compound and a preparation method, a pharmaceutical composition and the use thereof. In particular, the bis-?-carboline compound and a pharmaceutical salt thereof are described as general formula I, and the bis-?-carboline compound is prepared through the condensation of ?-carboline intermediate and dihaloalkane. Also disclosed in the present invention are a pharmaceutical composition comprising an effective dose of the bis-?-carboline compound as shown in formula I and a pharmaceutically acceptable carrier, and the use of the bis-?-carboline compound in preparing drugs resistant to tumors such as melanoma, stomach cancer, lung cancer, breast cancer, kidney cancer, liver cancer, oral epidermoid carcinoma, cervical cancer, ovarian cancer, pancreatic cancer, prostate cancer, and colon cancer.

Abstract: A direct-axis current protection method and device for a permanent magnet synchronous motor drive system. The method includes: pre-calculating the direct-axis current of the next moment according to the current voltage transmitted from an inverter to a permanent magnet synchronous motor (PMSM); comparing the direct-axis current of the next moment with a maximum protection current; if the direct-axis current of the next moment is less than the maximum protection current, continuing transmitting the current voltage to the PMSM; if the direct axis current of the next moment is greater than or equal to the maximum protection current, redistributing the voltage according to a protection direct-axis current and a protection quadrature-axis current, and transmitting the redistributed voltage to the PMSM. The direct-axis current of the next moment is tended to be normal by adjusting the voltage.

Abstract: A method and device for acquiring a rotor position based on a permanent magnet synchronous drive system. The permanent magnet synchronous drive system includes an inverter and a permanent magnet synchronous motor, wherein the initial speed of the permanent magnet synchronous motor is not zero. The method includes: controlling a bridge arm switch of an inverter periodically; collecting a three-phase current of the permanent magnet synchronous motor at a fixed time within each control period; and after the three-phase current is reversed, sending same to a phase-locked loop system to conduct processing, so as to obtain a phase angle of an induction potential vector, and according to the phase angle of the induction potential vector, acquiring a rotor position angle of the permanent magnet synchronous motor.

Abstract: The present disclosure provides methods and pharmaceutical compositions for treating depigmentation diseases such as vitiligo or leukoctricia. The pharmaceutical composition contains a therapeutically effective amount of fluoxetine.

Abstract: A rotor temperature monitoring method and system for a permanent magnet synchronous motor are provided. According to the method and system, an a-phase line current and a b-phase line current of a stator of a permanent magnet synchronous motor are obtained as a first line current and a second line current; further, a line voltage between the a-phase and the b-phase of the stator is obtained and a rotating speed of the rotor of the permanent magnet synchronous motor is obtained; and then, the first line current, the second line current, the line voltage, the rotating speed of the rotor, an inductance parameter of the permanent magnet synchronous motor and a temperature characteristic equation of a permanent magnet of the rotor are substituted into a preset rotor permanent magnet temperature expression to calculate and obtain the temperature of the rotor.

Abstract: Disclosed is a composition containing active components of Dracocephalum moldavica L. against myocardial ischemia-reperfusion injury (MIRI). The composition consists of active components and a pharmaceutically acceptable carrier, wherein the active components comprise luteolin, kaempferol and luteolin-7-O-glucoside. Pharmacodynamic experiments show that these three components can be combined together to synergistically treat myocardial ischemia-reperfusion injury.

Abstract: Disclosed are a compound pharmaceutical composition containing Cichorium glandulosum Boiss et Hout as a lipid-lowering active ingredient and the use of the composition for preparing a drug for treating or preventing lipid metabolism disorders, wherein the composition comprises a pharmaceutically active ingredient and a pharmaceutically acceptable carrier, wherein the pharmaceutically active ingredient consists of quercetin-3-O-?-D-glucuronoside, isoquercitrin and quercetin at a molar ratio of 1.1-2.4:1.3-3.3:1.2-3.1.